Navigation Links
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Date:6/1/2009

our study for patients taking VYVANSE during the double-blind treatment period, which were greater than or equal to 2 percent, were insomnia, decreased appetite, and anorexia.

VYVANSE Demonstrated Significant Efficacy Versus Placebo at 13 Hours Postdose

The study that led to this approval of revised labeling for VYVANSE was a randomized, double-blind, placebo-controlled, analog classroom study that assessed the efficacy and safety of VYVANSE in 129 children aged 6 to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with VYVANSE at 30 mg, 50 mg, and 70 mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of VYVANSE the first week and placebo the second week. The second group received placebo the first week and their optimal dose of VYVANSE the second week.

The primary objective of this study was to assess the time of onset of VYVANSE compared with placebo, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) rating scale. Secondary objectives included assessment of the duration of efficacy of VYVANSE compared with placebo, as measured by the SKAMP-D scale, and assessment of efficacy and time of onset of VYVANSE compared with placebo as measured by SKAMP Attention (SKAMP-A), and Permanent Product Measure of Performance (PERMP) scales.

In the study, VYVANSE demonstrated significant efficacy versus placebo at 1.5 hours, the first time point measured. Further, VYVANSE treatment was associated with significant efficacy as measured by both subjective (SKAMP-D and SKAMP-A) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day, and at all time points in between (2.5, 5.0, 7.5, 10.0 and 12.0 hours).

Safety was also evaluated during the stu
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
2. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
3. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. FDA Approves Label Change for Non-Invasive Fibroid Treatment
5. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
6. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
7. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
10. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
11. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... research team including DESY scientists has observed tiny quantum ... reports in the journal Science that the ... the nanodroplets. It is the first time that the ... samples of what is known as superfluid helium, have ... best expectations," says Andrey Vilesov of the University of ...
(Date:8/21/2014)... IA (PRWEB) August 21, 2014 His ... LIBERTY Opening , The Court of His Majesty Willem-Alexander, ... will attend the Grand Opening of POET-DSM Advanced Biofuels’ ... Wednesday, Sept. 3. , The King will take part ... opening activity, scheduled for 11 a.m.-12:20 p.m. and tour ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Fla., April 14 Phlo Corporation,(Pink Sheets: PHCP) ... stock certificates are negotiable in connection with,market transactions ... current,position in Phlo common stock. This clarification was ... number of brokers and clearing firms,will not negotiate ...
... in the second quarter of 2008 ... ... Ardea,Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data ... compounds demonstrating potent,activity against the human-immunodeficiency virus (HIV), including NNRTI-,resistant strains, with ...
... basis of blood-based ColonSentry(TM) test -, TORONTO, ... company focused on developing blood-based biomarker tests for ... today reported,positive performance results from a large validation ... of a patient,s current risk for,colorectal cancer. This ...
Cached Biology Technology:Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 3GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Journal of Animal Science , researchers evaluated how different levels ... to the researchers, the effects of selenium supplementation on the ... extensively in horses. Dr. Laurie Lawrence, animal science professor ... in soil and forages varies across the United States. She ...
... of consuming omega-3 long chain polyunsaturated fatty acids such ... sources of these fatty acids in the human diet ... of Saskatchewan, Department of Animal and Poultry Science are ... of farmed fish. As wild fish stocks ...
... reporting "a significant step forward" in proving the feasibility of ... for exotic new life forms. Their description of successful deployment ... seafloor lander equipped with a mini-laboratory the size of a ... of DNA in the deep oceans appears in ACS, ...
Cached Biology News:Researchers study selenium's effects on horses 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... ventilated and BR4i refrigerated multifunction centrifuges are equally ... at a low sound level with a large ... Their AUTO-LOCK rotor exchange system without tools ensures ... within seconds. Instant rotor exchange (5 ...
Biology Products: